What is Noble Financial’s Estimate for CRDF FY2025 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Noble Financial issued their FY2025 EPS estimates for Cardiff Oncology in a research note issued to investors on Monday, January 5th. Noble Financial analyst R. Leboyer expects that the company will post earnings of ($0.76) per share for the year. Noble Financial currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. Noble Financial also issued estimates for Cardiff Oncology’s FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.91) EPS and FY2030 earnings at $2.30 EPS.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.13.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $2.97 on Tuesday. Cardiff Oncology has a 52-week low of $1.90 and a 52-week high of $4.99. The business has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.58. The stock has a market cap of $200.06 million, a PE ratio of -3.76 and a beta of 1.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRDF. Acorn Capital Advisors LLC increased its position in Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Laurion Capital Management LP grew its stake in shares of Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after purchasing an additional 668,590 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after purchasing an additional 9,740 shares during the last quarter. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology in the third quarter valued at approximately $26,000. Finally, AlphaCore Capital LLC raised its position in Cardiff Oncology by 8.2% in the 3rd quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock worth $226,000 after purchasing an additional 8,351 shares during the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.